Allena Pharmaceuticals secures $15 million in Series A financing

Wednesday, November 16, 2011 03:03 PM

Allena Pharmaceuticals, a company developing and commercializing innovative non-systemic oral protein therapeutics, has secured $15 million in Series A venture capital financing. Bessemer Venture Partners, Frazier Healthcare and Third Rock Ventures led the round. Proceeds from the financing will be used to accelerate the development of Allena's non-systemic protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions.

"We see Allena as an opportunity to create a world-class pharmaceutical company driven by a proven technical approach and strengthened by innovative research and science," said Robert Tepper, M.D., partner, Third Rock Ventures. "Our experience working with this team in the past has yielded tangible success, including the acquisition of Alnara by Eli Lilly & Co. in 2010, and we look forward to working with Allena to create value and positively impact the lives of patients."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs